8-KFiled Sep 21, 8:00 PM ET

Filana Therapeutics Issues Press Release Under Regulation FD

$FLNA · FILANA THERAPEUTICS, INC.

Research Summary

AI-generated summary of this SEC filing

Updated

Filana Therapeutics Issues Press Release Under Regulation FD

What Happened

  • Filana Therapeutics, Inc. (FLNA) filed a Form 8-K on September 22, 2026, disclosing that the company issued a press release under Regulation FD. The press release is attached to the filing as Exhibit 99.1 and is incorporated by reference into the report.

Key Details

  • Filing date: September 22, 2026 (Form 8-K, accession no. 0001171843-26-006161).
  • Item reported: 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events).
  • Exhibit furnished: 99.1 — the press release issued by Filana Therapeutics on September 22, 2026.
  • The filing also includes the interactive XBRL cover page (Exhibit 104).

Why It Matters

  • Regulation FD (Fair Disclosure) filings indicate the company shared information publicly so all investors have equal access; the attached press release may contain material updates.
  • Retail investors should read Exhibit 99.1 (the press release) to see any details or developments that could affect the company’s outlook or stock.
  • This 8-K does not itself report financial results or executive changes; it primarily documents the public release of information.